Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer
Autor: | Yesol Kim, Hyeok Gu Kang, Hyun Kyung Kong, Yonghwan Kim, Kyung Hyun Yoo, Jong Hoon Park, Da Hyun Kim, Jee Won Park, Lim Sera, Wonshik Han, Daeun Chung, Kyung-Hee Chun, Soo Been Lee |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Genome instability Cancer Research DNA damage DNA damage response lcsh:RC254-282 Article Non-coding RNAs 03 medical and health sciences 0302 clinical medicine Breast cancer medicine CHEK1 Molecular Biology Triple-negative breast cancer business.industry medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Oxaliplatin 030104 developmental biology Tumor progression 030220 oncology & carcinogenesis Cancer cell Cancer research business medicine.drug |
Zdroj: | Oncogenesis Oncogenesis, Vol 9, Iss 10, Pp 1-14 (2020) |
ISSN: | 2157-9024 |
Popis: | Checkpoint kinase 1 (Chk1) expression is enhanced in most cancers owing to oncogenic activation and constant replicative stress. Chk1 inactivation is a promising cancer therapy, as its inactivation leads to genomic instability, chromosomal catastrophe, and cancer cell death. Herein, we observed that miR-320c, downregulated in triple-negative breast cancer (TNBC) patients, can target Chk1. In addition, downregulated miR-320c expression was associated with poor overall survival in TNBC patients. As Chk1 was associated with the DNA damage response (DDR), we investigated the effect of miR-320c on DDR in TNBC cells. To induce DNA damage, we used platinum-based drugs, especially oxaliplatin, which is most effective with miR-320c. We observed that overexpression of miR-320c in TNBC regulated the oxaliplatin responsiveness by mediating DNA damage repair through the negative regulation of Chk1 in vitro. Furthermore, using a xenograft model, a combination of miR-320c mimic and oxaliplatin effectively inhibited tumor progression. These investigations indicate the potential of miR-320c as a marker of oxaliplatin responsiveness and a therapeutic target to increase the efficacy of chemotherapy in TNBC. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |